Very excited to announce that I’ve joined the team as Business Insider’s first UK healthcare reporter! I’ll be covering European healthcare business for @businessinsider, closely tracking vaccines, start-ups and everything digital health. My DMs are open - go!
@jesse_yeji and I asked VCs in psychedelics to name the most promising startups in the field.
Click through to see the companies that made the list (and why)!
Are there others that you're excited about? Why?
https://t.co/23M7mEoiyl
The hottest startups in psychedelics, according to investors 👀👀👀
It's been a tough market for the psychedelics industry. But, during the downturn, venture capitalists are continuing to invest in companies they say are promising...
Meet the top VCs in the psychedelics space!
@jesse_yeji and I wanted to know who wrote the most cheques.
We asked around 25 firms how many deals they've made and how much money they've invested in the space, among other questions. (1)
We narrowed our list to 14 firms by including only funds that invested at least $5 million into psychedelics companies and had portfolios made up of at least 30% psychedelics startups.
@KeysToTheBank Hi Mike, I'm a journo from Insider. I hope you don't mind us contacting you. We've read about your story and would love to interview you about your experiences. I'm on [email protected] - thank you!
We don't rely on press releases/statements: every few months @drcatherinesb and I contact each company on our tracker & reach out to new ones to ask when we should expect more data, how their trials are faring, and how much $ they have on hand to continue backing their studies
🧵#ScienceBreakdown: "Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors"
Interesting new paper by @DEOlsonLab, @LinTianPhD, et al. looking at why some serotonin 2A receptor agonists promote neuroplasticity, but others do not.
1/
It might be the middle of July, but the healthcare team @BusinessInsider has been busy this week putting out fascinating reads on the future of the industry. (thread!)
Here are some of the most influential regulators, advocates, and executives shaping the first ever regulated psilocybin market in the US.
Latest from me & @drcatherinesb:
https://t.co/u3iarlvtPJ
Who is deciding what legal "magic" mushrooms in the US might look like? We looked to Oregon to find out. https://t.co/dKBGpYtDnY @jesse_yeji@HealthInsider
There's hundreds of studies and a whole load of hype around the potential to transform compounds like MDMA and psilocybin into new medical treatments that might be prescribed to millions of people with health conditions for which there are few good options right now.. (A thread!)
We took a long hard look at the psychedelics clinical trials furthest along in the regulatory pathway and put together an analysis of what we found.
Latest from @drcatherinesb & me: (1/11)
https://t.co/f1alteWYrF
Putting all these reports together has been a mammoth team effort. Big big thank you to @ZTracer and the fantastic graphics team: Shayanne Gal, Annie Fu, and Alex Ford.